ALLAN JONATHAN PANTUCK, M.D., M.S., F.A.C.S.
`
`Curriculum Vitae
`
`
`
`
`
`February 4, 1967
`
` New York, NY
`
`
`
`
`
`
`
` Institute for Urologic Oncology
`Third Floor Wasserman Building
` 300 Stein Plaza
` Los Angeles, CA 90095
`
` 2012 Walgrove Avenue
` Los Angeles, CA 90066
`
`
`
` Married, two children.
`
` 310-206-2436
`310-794-3513
`Apantuck@mednet.ucla.edu
`
`
`PERSONAL DATA
`
`Date of birth:
`
`Place of birth:
`
`Business Address:
`
`
`
`
`Home Address:
`
`
`Marital status:
`
`Business Telephone:
`Business Fax:
`E-Mail:
`
`UNDERGRADUATE EDUCATION
`
`Columbia University,
`B.A., 1989
`
`GRADUATE EDUCATION
`
`University of Medicine and Dentistry of New Jersey,
`Robert Wood Johnson Medical School
`Piscataway, NJ
`M.D., 1993
`
`UCLA David Geffen School of Medicine
`Master’s Degree in Clinical Research
`Los Angeles, CA
`M.S., 2005
`
`
`
`1
`
`Breckenridge Exhibit 1028
`Pantuck CV
`Page 001
`
`

`

`PROFESSIONAL
`
`Residency
`University of Medicine and Dentistry of New Jersey,
`New Brunswick, NJ
`
`1993-1994
`
`
`
`1994-1995
`
`
`
`1995-1998
`
`
`
`1998-1999
`
`
`
`1999-2002
`
`
`
`
`2001-2002
`
`Intern, Division of General Surgery.
`UMDNJ
`New Brunswick, NJ
`
`Resident, Division of General Surgery.
`UMDNJ
`New Brunswick, NJ
`
` Resident, Division of Urology.
`UMDNJ
`New Brunswick, NJ
`
` Chief Resident, Division of Urology.
`UMDNJ
`New Brunswick, NJ
`
`Fellowship in Urologic Oncology.
`Department of Urology
`UCLA School of Medicine
`Los Angeles, CA
`
`Fellowship
`K30 Graduate Training Program in Translational Investigation
`UCLA School of Medicine
`Los Angeles, CA
`
`1995-1999
`1999-Present
`
`
`MEDICAL LICENSURE
`
`New Jersey MA062447
`California G085029
`
`CERTIFICATIONS
`
`DEA # BP4590611
`
`Diplomate, National Board of Medical Examiners, 1994.
`
`The New Jersey Kidney Stone Treatment Center ESWLithotripsy Training Program, 1999.
`California fluoroscopy supervisor and operator, 2000-2002.
`
`
`2
`
`Breckenridge Exhibit 1028
`Pantuck CV
`Page 002
`
`

`

`Investigator responsibilities toward Investigational Review Board (IRB) and regulatory concerns
`with an emphasis on conducting clinical research in gene based medicine, 2000-2002.
`
`University of California Los Angeles, Certificate of Completion, Training in Protecting Human
`Research Subjects, 2000-2002.
`
`UCLA, Certificate of Completion, Good Manufacturing Practice and Good Laboratory Practice,
`2001-2003.
`
`University of California HIPAA Training, 2003.
`
`Society of Urologic Oncology Fellowship Certification, 2002.
`
`Diplomat, American Board of Urology, 2004, re-certified: 2013.
`
`Fellow, American College of Surgeons, 2005.
`
`ACADEMIC APPOINTMENTS
`
`2015 Professor, Step 2, UCLA Department of Urology
`
`2012 Professor, Step 1, UCLA Department of Urology
`
`2010
`
`2008
`
`2006
`
`2004
`
`2002
`
`2001
`
`1999
`
`CLINICAL APPOINTMENTS
`
`2014-Present Attending Urologist, Martin Luther King, Compton, CA
`
`2003–2010
`
`2001–Present Attending Urologist, UCLA Medical Center, Los Angeles, CA
`
`
`
`Attending Urologist, Harbor-UCLA Medical Center, Torrance, CA
`
`Clinical Instructor, UCLA Department of Urology
`
`3
`
` Associate Professor, Step 3, UCLA Department of Urology
`
`Associate Professor, Step 2, UCLA Department of Urology
`
`Associate Professor, Step 1, UCLA Department of Urology
`
`Assistant Professor, Step 4, UCLA Department of Urology
`
`Assistant Professor, Step 3, UCLA Department of Urology
`
` Visiting Assistant Professor, UCLA Department of Urology
`
`Breckenridge Exhibit 1028
`Pantuck CV
`Page 003
`
`

`

`Attending Urologist, UCLA Santa Monica Medical Center, Santa Monica, CA
`
`Attending Urologist, Wadsworth Veterans Affairs Medical Center,
`Los Angeles, CA
`
`2001–2003
`
`1999–2010
`
`
`PROFESSIONAL ACTIVITIES:
`
`2016
`
`Kidney Cancer Abstract Reviewer, 2017 American Urological Assocation
`annual meeting.
`
`AUA Rising Stars in Urology grant reviewer
`
`Society of Urologic Oncology program committee member and session
`moderator
`
`Kidney Cancer Abstract Reviewer, 2016 American Urological Assocation
`annual meeting.
`
`Urology Care Foundation Review Panel
`
`Kidney Cancer Abstract Review Team Leader, 2015 American Urological
`Assocation annual meeting.
`
`Kidney Cancer Abstract Review Team Leader, 2014 American Urological
`Assocation annual meeting.
`
`Grant Reviewer, Austrian Science Fund
`
`Moderator, RCC Evaluation and Staging, American Urological Assocation
`annual meeting, 2013.
`
`Abstract Review Team Leader, 2013 American Urological Assocation annual
`meeting.
`
`Moderator, RCC Evaluation and Staging, American Urological Assocation
`annual meeting, 2012.
`
`Abstract Review Team Leader, 2011 American Urological Assocation annual
`meeting.
`
`Society of Urologic Oncology Program Committee
`
`Instructor, American Urological Association CME course on management of
`small renal tumors.
`
`4
`
`
`2016
`
`2016
`
`
`2015
`
`
`2014
`
`2014
`
`
`2013
`
`
`2013
`
`2013
`
`
`2012
`
`
`2012
`
`
`2011
`
`
`2010
`
`2010
`
`
`
`
`Breckenridge Exhibit 1028
`Pantuck CV
`Page 004
`
`

`

`Instructor, American Urological Association CME course on management of
`small renal tumors.
`
`Society of Urologic Oncology Program Committee
`
`ASCO GU Meeting RCC Program Committee
`
`Kidney Cancer Prognostic Factor Committee, Societe Internationale d’Urology
`
`Co-Director, UCLA Integrative Urology Program
`
`American Urological Association Complementary and Alternative Medicine
`Committee
`
`Southwest Oncology Group (SWOG) Genitourinary Committee
`
`American College of Surgeons Oncology Group GU Committee
`
`2009
`
`
`2008–Present Society of Urologic Oncology Clinical Trials Consortium Kidney Cancer
`
`Committee
`
`2008
`
`2008
`
`2007
`
`2006
`
`2006–Present Program Abstract Review Committee, American Urological Association
`
`2005–2009
`
`
`2003
`
`2003
`
`HOSPITAL/UNIVERSITY COMMITTEES:
`
`2016-Present Executive Chair, UCLA Medical Institutional Review Board-2
`
`2016-Present Voting member, UCLA Human Research Policy Board
`
`2015
`
`MedTech Innovation Fellow Program panel judge, UCLA Business of Science,
`Center California Nano Systems Institute, Anderson Business School
`
`
`2013-Present UCLA Department of Urology Director of Faculty Academic Affairs
`
`2013-Present Society of Urologic Oncology Fellowship Director
`
`2013-Present UCLA Clinical Research Governance Committee
`
`2013-2014 UCLA Cancer Theme Steering Committee
`
`2013
`
`Mellinkoff Faculty Award/Leonard Tow Humanism in Medicine Award
`Selection Committee
`
`
`2013-Present UCLA Clinical Research Compliance Committee
`
`
`
`
`5
`
`Breckenridge Exhibit 1028
`Pantuck CV
`Page 005
`
`

`

`JCCC Clinical Research Unity Faculty Advisory Group
`
`JCCC Translational Oncology Research International (TORI) Network Review
`Committee
`
`Ad Hoc Research Misconduct Committee
`
`JCCC Seed Grant Review Committee
`
`Jonsson Comprehensive Cancer Center Radiation Task Force
`
`2012-Present UCLA Department of Urology Finance Committee
`
`2012-Present UCLA Urology Education Committee
`
`2011-Present Executive Vice Chair, UCLA Medical Institutional Review Board-2
`
`2011
`
`2011
`
`
`2009
`
`2008-2012
`
`2008
`
`2007-Present Program Leader GU Oncology Program, UCLA Jonsson Comprehensive Cancer
`
`Center
`
`Jonsson Comprehensive Cancer Center Seed Grant Committee
`2007-Present
`2006-Present Director of Tranlsational Research, UCLA Kidney Cancer Program
`
`2005-Present Scientific Review Committee for Human Embryonic Stem Cell Research
`
`2004-Present UCLA Medical Institutional Review Board-2
`
`2003-2010
`
`
`2003-Present
`
`Jonsson Comprehensive Cancer Center (JCCC) Internal Scientific Peer Review
`Committee (ISPRC).
`
`Jonsson Comprehensive Cancer Center (JCCC) Data and Safety Monitoring
`Board (DSMB).
`
`Clinical Trials Working Group, UCLA Department of Urology.
`
`
`2000
`
`
`
`
`
`OPTIMAP Critical Care Pathway Committee for TURP, TURBT, Radical
`prostatectomy, Radical cystectomy with ileal conduit and continent urinary
`diversion, Robert Wood Johnson University Hospital.
`
`1995-1998
`
`
`
`PROFESSIONAL SOCIETIES & MEMBERSHIPS:
`
`American Association for Cancer Research
`Fellow, American College of Surgeons
`American Society of Clinical Oncology
`
`
`6
`
`Breckenridge Exhibit 1028
`Pantuck CV
`Page 006
`
`

`

`American Urological Association
`International Churchill Society
`Western Section American Urological Association
`Member, Southwest Oncology Group (SWOG)
`Member, Jonsson Comprehensive Cancer Center
`Member, UCLA Center for Integrative Medicine
`International Society for Biological Therapy of Cancer
`Member, Society of Urologic Oncology
`
`EDITOR:
`
`Advances in the Management of Renal Cell Carcinoma. Proceedings of the Irish Society of
`Surgical Oncology. Excerpta Medical International. The Netherlands, 2003.
`
`Guest Editor, Kidney Cancer special issue, World Journal of Urology, May, 2014.
`
`European Association of Urology-International Consortium for Urologic Diseases: Medical
`Treatment of Urological Malignancies (MTUM) Committee on Advanced Kidney Cancer –
`Immunotherapy, 2015.
`
`REVIEWER:
`
`The Journal of Urology
`Urology
`British Journal of Urology International
`The Journal of Cancer Integrative Medicine
`European Urology
`Urologic Oncology
`Clinical Cancer Research
`BCW Clinical Pathology
`Nutrition and Cancer
`Canadian Institutes of Health Research
`The Indian Journal of Urology
`
`EDITORIAL BOARD SERVICE:
`
`Board of Reviewers, Laboratory Research Survey Section, Urologic Oncology: Seminars and
`Original Investigations
`The Journal of Cancer Integrative Medicine
`The Bladder Journal
`American College of Physicians Information and Education Resource
`European Urology
`Kidney Cancer Journal
`Clinical Medicine: Urology
`
`
`
`
`7
`
`Breckenridge Exhibit 1028
`Pantuck CV
`Page 007
`
`

`

`CONSULTANCY:
`
`Galil Medical Ltd., Yokneam, Israel
`Vical Corporation, San Diego, CA
`Chiron Corporation, Emoryville, CA
`Wilex Corporation, Munich, Germany
`Gerson Lehrman Group Council Member
`Cougar Biotechnology, Los Angeles, CA
`Pfizer, New York, NY
`Health Ever Bio-Tech Co., Ltd, Taipei, Taiwan.
`Prometheus, San Diego, CA
`
`BIOTECHNOLOGY AFFILIATIONS:
`
`Kite Pharma (Co-Founder and Special Clinical Advisor)
`Fibron Technologies, Inc (Scientific Advisory Board)
`IDxVentures (Scientific Advisory Board)
`
`HONORS/AWARDS:
`
`2013
`
`
`2012
`
`
`2012
`
`
`2008
`
`2008
`
`
`2007
`
`
`
`
`
` Best poster: Renal tumours: Basic research in prognostic markers: High
`cytoplasmic and low nuclear expression of HIF-2α are associated with worse
`cancer specific survival (CSS) in clear cell renal cell carcinoma. European
`Association of Urology, 28th Congress, Milan, Italy, March 11, 2013.
`
`Maximilian Nitze Award for the project titled “Clinical, Molecular, and Genetic
`Correlates of Lymphatic Spread in Clear Cell Renal Cell Carcinoma”. The
`Maximilian Nitze Award is the highest scientific honor awarded by the German
`Society of Urology for outstanding scientific achievements in experimental or
`clinical urology (Awardee: Nils Kroeger; Mentor: Pantuck).
`
`Best Poster in Kidney Cancer – Basic Research II Session – AUA Annual
`Meeting 2012, “DC-Ad-GMACAIX Based Vaccine Therapy is Safe and
`Effective in Immunocompetent Murine Kidney Cancer Tumor Models.”
`Birkhäuser F, et al.
`
`Best Scientific Paper Published in European Urology in 2007.
`
`First Prize, best poster, Renal tumours: surgical treatment and prognosis,
`European Association of Urology, Milan, Italy.
`
`First Prize, best poster, Kidney Cancer Evaluation and Treatment, American
`Urological Association annual meeting, Anaheim, California.
`
`8
`
`Breckenridge Exhibit 1028
`Pantuck CV
`Page 008
`
`

`

`2007
`
`
`2004
`
`
`2003
`
`
`2003
`
`
`2003
`
`2002
`
`
`2002
`
`
`
`
`
`
`
`
`
`Second Prize, best oncology abstract, European Association of Urology annual
`meeting, Berlin, Germany.
`
`Second place, Miley B. Wesson Essay Contest, Western Section American
`Urological Association, San Diego, CA, senior author.
`
` Second place, AUA/ACMI clinical essay contest. American Urological
`Association Annual Meeting, Chicago, fourth author.
`
`Third place, AUA/ACMI clinical essay contest. American Urological
`Association Annual Meeting, Chicago, third author.
`
`American Society of Clinical Oncology Merit Award, 2nd author.
`
`Second Prize, Joseph F. McCarthy essay contest, Western Section American
`Urological Association, 2nd author.
`
`First Prize Winner, Miley Wesson/Proctor and Gamble Resident Essay contest,
`Western Section American Urological Association, 4th author.
`
` American Society of Clinical Oncology Merit Award, 1st author.
`
` American Society of Clinical Oncology Merit Award, 2nd author.
`
` Pfizer Scholars in Urology Award.
`
` Third Prize, Basic Science Category, The Philadelphia Urological Society
`
`Pfizer Scholars in Urology Award.
`
`Gallo Award, Clinical Oncology, Cancer Institute of New Jersey, Scientific
`Retreat.
`
`Second prize, Clinical Research, American Urological Association Prize Essay
`Contest Competition.
`
`Pantuck (Co-PI)
`Department of Defense
`UCLA Clinical Trials Research Site, DoD Clinical Trials Consortium
`Role: Co-Principal Investigator, Award $500,000
`
`
`2002
`
`2001
`
`1999
`
`1998
`
`1997
`
`1993
`
`
`1991
`
`
`GRANTS and RESEARCH SUPPORT
`
`2014-2017
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`9
`
`Breckenridge Exhibit 1028
`Pantuck CV
`Page 009
`
`

`

`2013-2014
`
`
`
`2012-2013
`
`
`Pantuck (PI)
`Amgen
`Tissue Microarray Study of RANK Ligand and Receptor Expression in
`Localized and Metastatic Renal Cell Carcinoma
`Role: Principal Investigator; Award: $150,000
`
`Pantuck (PI)
`UC Cancer Research Coordinating Committee
`Rationally based combination immunotherapy: Active specific dendritic based
`vaccine (DC-Ad-GM·CAIX) and immune-checkpoint blockade targeting the
`PD1/PD-L1 pathway
`Role: Principal Investigator; Award: $50,000
`
`
`2012-2016 Zeng (PI)
`NIH/NCI R01
`A+PSA for improved prostate cancer diagnosis and risk assessment.
`This grant application will further test the A+PSA autoantibody assay as a test
`for improving diagnosis and risk assessment in prostate cancer.
`Role: Sub-Investigator
`Annual Direct Costs: $250,000
`
`Pantuck (PI)
` Novel Mitochondrially Encoded Peptides and Their Interaction with the
`Naturally Occurring Nutrients in Pomegranate
`Role: Principal Investigator; Award: $40,000
`
`2012-2013
`
`
`2011-2014.1 Pantuck (PI)
`Department of Defense
`CA100606PI-Early diagnosis of clear cell kidney cancer using VHL/HIF
`pathway regulated circulating microRNA.
`This is an Idea Award which seeks to identify a panel of microRNAs that are
`measurable in serum for the early diagnosis of kidey cancer.
`Role: Principal Ivestigator
`Award: $241,590
`
`2011-2016 NIH NCI R01 Biopsy Tracking and
` MRI Fusion to Enhance Imaging of Cancer Within the Prostate
` Role: SubI (PI Marks)
` Total direct costs: $390,327.00
`
`2011-2013 National Science Foundation SBIR
`
` Phase II Polyaniline nanofiber urinary tract infection biosensor
` Role: subcontract PI (PI: Pantuck)
` Total direct costs: $150,000
`
`
`
`
`10
`
`Breckenridge Exhibit 1028
`Pantuck CV
`Page 0010
`
`

`

`Pantuck (PI)
`US HIFU
`USE OF FOCUSED ULTRASOUND AS AN ADJUVANT TO AUGMENT
`ANTI-CANCER ACTIVITY
`Role: PI @ 5% effort= 0.6 calendar
`Total direct costs: $35,000
`
`Rao (PI)
`NIH ARRA
`Global genetic and epigenetic approaches to progression of PCa
`Role: Sub-investigator @ 5%= 0.6 calendar
`Total Direct costs: $160,000
`
`Anger (PI)
`NIH ARRA 1 RC1
`Comparative Efficacy of Robotic versus Open Sacrocolpopexy for Vaginal
`Vault Prolapse
`Role: Co-PI @ 10% effort= 1.2 calendar
`Total direct costs: $382,569
`
`Pantuck (PI)
`National Science Foundation SBIR
`Polyaniline nanofiber urinary tract infection biosensor
`Role: subcontract PI @ 5% effort= 0.6 calendar
`Total direct costs: $50,000
`
`Zeng (PI)
`NIH NCI R21
`Auto-antibody plus PSA assay for patients with prostate cancer
`Role Sub-Investigator @ 5% effort= 0.6 calendar
`Annual Direct costs: $132,000
`
`Reiter (PI)
`NIH NCI P50
`UCLA Prostate Cancer SPORE
`This is a competitive renewal application for the UCLA multidisciplinary
`Prostate Cancer SPORE program
`Role: Sub-Investigator @ 10% effort= 1.2 calendar
`Annual Direct Costs: $2,200,000
`
`Novartis: Flourescent In Situ Hybridization Study of Chromosome 9p in the
`UCLA Kidney Cancer Tissue Microarray. $75,000 (PI: Pantuck)
`
`11
`
`2010-2011
`
`2009–2010
`
`2009–2010
`
`2009-2010
`
`
`2009–2010
`
`
`2007-2012
`
`
`
`2007-2008
`
`
`
`
`
`Breckenridge Exhibit 1028
`Pantuck CV
`Page 0011
`
`

`

`Sense Foundation: Evaluation of the Mechanisms of Pomegranate
`Polyphenol-Mediated Suppression of Nuclear Factor kappa B(NF-
`B)Activity. $140,000 (PI Pantuck)
`
` Randomized, double blind, placebo controlled phase III study of pomegranate
` juice (Pom Wonderful) for men with rising PSA following surgery or
`radiation.
`$490,750 (PI Pantuck)
`
`US Army/DoD IDEA Grant. A Novel Assay of Citrate, Choline, and
`Spermine in Prostate Cancer $375,000(PI Thomas)
`
` Phase I Organization: Phase I study of adenovirus GM-CSF-CA IX modified
`autologous DCs for metastatic kidney cancer. $250,000. (Co-PI: Pantuck)
`
`Pom-Wonderful: Estrogenic activity of pomegranate seeds
`$15,525. (PI: Pantuck)
`
`Amgen Corporation: Protein Biomarker evaluation of
`Renal Cell Carcinoma. $109,000. (PI: Pantuck)
`
`Gasson (PI)
`NIH P30
`UCLA NCI designated Comprehensive Cancer Center support grant
`This is a competing renewal for the UCLA designated Comprehensive Cancer
`Center support grant.
`Role: Sub-Investigator/GU Program Director @ 10% effort= 1.2 calendar
`Annual Direct costs: $3,077,679
`
`NIH RFA: Chemoprevention of Superficial Bladder
`Cancer. $7,466,331 (PI: Belldegrun)
`
`NIH K23 Research Career Development Award: Genetic
`and Molecular Characterization of kidney cancer.
`$540,000 (PI: Pantuck)
`
`Department of Defense. Molecular Characterization of
`Androgen Independence to Delay Progression to Hormone
`Refractory Prostate Cancer. $572,000. (PI: Belldegrun).
`
` Chiron Corp. Pilot study of ability of IL-2 to
`clear circulating tumor cells in patients with
`metastatic renal cell carcinoma.$57,000(PI:Pantuck).
`
`12
`
`2007-2008
`
`
`2005-2007
`
`
`2004-2008
`
`
`2004-2006
`
`
`2004-2005
`
`
`
`2003-2004
`
`
`2002-2012
`
`2002-2007
`
`
`2002-2006
`
`
`
`2002-2005
`
`
`
`
`2002-2004
`
`
`
`
`
`
`
`Breckenridge Exhibit 1028
`Pantuck CV
`Page 0012
`
`

`

`2002-2004
`
`
`
`2002-2004
`
`
`2002-2003
`
`
`2001-2003
`
`
`
`
`2001-2003
`
`
`
`
`2001-2002
`
`
`2001-2002
`
`
`
`
`
` Pom-Wonderful: Pomegranate juice to stop or slow the
`progression of prostate cancer in men with rising PSA
`after failed primary therapy. $347,000. (PI: Pantuck)
`
`Transgene: Randomized Multicenter Phase II Study Evaluating Two Dosing
`Schedules of TG4010 (MVA-MUC1-Il2) in Patients with Adenocarcinoma of
`the Prostate (TG4010.03). $101,299. (PI: Pantuck)
`
`Xcyte: A Phase I Safety Study of Xcellerate in Patients with Hormone
`Refractory Prostate Cancer. $113,533 (PI: Pantuck)
`
`Ortho-Biotech Perioperative recombinant human erythropoietin for patients
`undergoing radical nephrectomy followed by an FDA approved schedule of
`IL-2. Protocol PR00-28-042.
`$185,000. (PI: Pantuck)
`
`MD Anderson Cancer Center/Charles Dana
`Foundation. The effect of psychosocial factors on
`survival in patients with metastatic renal cell
`carcinoma. $30,000. (UCLA PI: Pantuck).
`
`Robert Winston Seed Money for Complementary Medicine
`Research. $100,000 (Co-PI: Pantuck).
`
`EMD Pharmaceuticals. High Throughput analysis using
`tissue microarrays to determine the expression of KS
`antigen in normal kidney, primary renal cell carcinoma,
`and metastatic renal cell carcinoma. $137,000
`(PI:Pantuck)
`
`K12 National Research Service Award Cancer Gene
`Medicine Training Program. Total funding $175,000.
`(PI: Economou).
`
`American Foundation for Urologic Disease
`Summer Student Research Fellowship.
`
`
`1999-2002
`
`
`
`1990
`
`
`INVITED LECTURES:
`
`1.
`
`Management of esoteric penile injuries. Department of Urology, New Jersey Medical
`School. Newark, NJ. August 8, 1997.
`
`Evaluation of hematuria. UCLA School of Medicine. July 30, 1999.
`
`Nutrition and prostate cancer. UCLA Prostate Cancer Education Group. September 9,
`
`13
`
`
`
`
`
`2.
`
`3.
`
`Breckenridge Exhibit 1028
`Pantuck CV
`Page 0013
`
`

`

`1999.
`
`Current controversies in the surgical management of renal cell carcinoma. Chiron/UCLA
`Kidney Cancer Program Preceptership. Los Angeles, CA. September 12, 1999.
`
`Immune and Gene Therapy for Renal Cell Carcinoma. Plenary lecture, Basic Oncology.
`Okinawa Urologic Research Forum. Okinawa, Japan. January 29, 2000.
`
`Gene therapy for kidney cancer. Chiron/UCLA Kidney Cancer. Program Preceptership.
`Los Angeles, CA. March 12, 1999.
`
`Hormone refractory prostate cancer. UCLA Prostate Cancer Education Group. April 13,
`2000.
`
`Bladder cancer 2000: new directions. Marian Medical Center Cancer Forum. Santa
`Maria, CA. November 10, 2000.
`
`Hormone therapy for prostate cancer: when to start? UCLA Prostate Cancer Education
`Group. January 8, 2001.
`
`The role of nephrectomy in renal cancer biology. Immunotherapy of Renal Cancer
`Workshop. Hospital Universitario Virgen de las Nieves. Granada, Spain. February
`17, 2001.
`
`The role of nephrectomy in metastatic renal cell carcinoma. Baylor University, Houston,
`TX. March 14, 2001.
`
`Optimizing prostate cancer gene therapy using Herpes Simplex Virus 1 Thymidine
`Kinase Gene Mutants. Sixth Annual Gene Medicine Symposium, UCLA School of
`Medicine. May 21, 2001.
`
`The role of nephrectomy in advanced renal cell carcinoma. Jefferson Medical School.
`Philadelphia, PA. January 24, 2002.
`
`Complementary Medicine and Prostate Cancer. Midway Hospital. Los Angeles, CA.
`September 16, 2002.
`
`The role of nephrectomy and immunotherapy in metastatic renal cell carcinoma. Tampa
`VA Hospital, Tampa, FL. September 18, 2002.
`
`Complementary medicine in prostate cancer. Harbor Hospital. Torrance, CA. October 3,
`
`14
`
`
`4.
`
`
`5.
`
`
`6.
`
`
`7.
`
`
`8.
`
`9.
`
`
`
`10.
`
`
`12.
`
`13.
`
`
`14.
`
`15.
`
`
`16.
`
`17.
`
`
`
`
`
`11. Management of advanced renal cell carcinoma. Mayo Clinic. Rochester, MN. February
`19, 2001.
`
`Breckenridge Exhibit 1028
`Pantuck CV
`Page 0014
`
`

`

`2002.
`
`Complementary medicine in urology. Valley Presbyterian Hospital. Los Angeles, CA.
`October 8, 2002.
`
`
`19. Molecular in vivo imaging of prostate cancer using green fluorescence protein. 9th Prouts
`Neck Meeting on Prostate Cancer. Prouts Neck, Maine. November 10, 2002.
`
`
`18.
`
`
`20.
`
`
`21.
`
`
`22.
`
`23.
`
`
`24.
`
`
`25.
`
`
`26.
`
`27.
`
`
`28.
`
`
`30.
`
`
`
`31.
`
`Phase III study of Iressa and green tea polyphenol extracts in the chemoprevention of
`smoking related, superficial bladder cancer. Society of Urologic Oncology, Bethesda,
`MD. December 7, 2002.
`
`Prognostication and Clinical Outcome Algorithms for Renal Cell Carcinoma. Irish
`Society of Surgical Oncology. Dublin, Ireland. January 24, 2003.
`
`The Role of Nephrectomy and Immunotherapy in a Combined Approach to Metastatic
`Kidney Cancer. Irish Society of Surgical Oncology. Dublin, Ireland. January 24, 2003.
`
`Prostate Nerve block for transrectal ultrasound guided prostate needle biopsy. UCLA
`State of the Art, February 9, 2003.
`
`Clinical outcome algorithms and the role of nephrectomy and immunotherapy in
`metastatic kidney cancer. Baylor University Medical Center. Dallas, TX. March 21,
`2003.
`
`Recent developments in the treatment of kidney cancer. Chiron Sales Education Network.
`May 21, 2003.
`
`Changing Concepts in the Management of Metastatic RCC. Howard University.
`Washington, DC. October 28, 2003.
`
`The UCLA Integrated Staging System. Conference on the Multidisciplinary approach to
`the Treatment of Metastatic Renal Cell Carcinoma. Sintra, Portugal. November 25, 2003.
`
`Prostate Cancer Prevention 2004: Marian Medical Center. Marian, CA, 2004.
`
`Nonsurgical techniques for managing small renal lesions. First International Congress on
`
`Nephrectomy and Interleukin-2 for Metastatic RCC. Conference on the Multidisciplinary
`approach to the Treatment of Metastatic Renal Cell Carcinoma. Sintra, Portugal.
`November 25, 2003.
`
`29. Moderator: Prostate Cancer Epidemilogy and Natural History. American Urological
`Association, San Francisco, CA, 2004.
`
`
`
`15
`
`Breckenridge Exhibit 1028
`Pantuck CV
`Page 0015
`
`

`

`Bladder and Kidney Cancer. Orlando, FL. August 13, 2004.
`
`Interferon vs. IL-2 follwing nephrectomy for metastatic renal cell carcinoma. First
`International Congress on Bladder and Kidney Cancer. Orlando, FL. August 14, 2004.
`
`Update on the Treatment of RCC. Shin-Kong Wu-Su Memorial Hospital, Taipei, Taiwan,
`August 27, 2004.
`
`The Role of Combined Nephrectomy and Immunotherapy for Metastatic RCC. Special
`Lecture, Taiwan Urological Association, Taipei, Taiwan, August 28, 2004.
`
`Update on RCC Staging Algorithms and New Surgical Approaches to the Management of
`Small Renal Masses. National Taiwan University, Taipei, Taiwan, August 30, 2004.
`
`Prostate Cancer and Pomegranate Juice: Preclincal and Clinical Data, Future Directions.
`Prostate Cancer Foundation 11th Annual Scientific Retreat. Lake Tahoe, Nevada, October
`24, 2004.
`
`Immunohistochemical analysis of the mTOR pathway in Renal Cell Carcinoma. Wyeth,
`Cambridge, MA, January 17, 2005.
`
`Prostate Cancer and Pomegranate Juice: Preclincal and Clinical Data, Phase III Study.
`Prostate Cancer Foundation Investigator’s Meeting. Santa Monica, CA. February 4, 2005.
`
`Transrectal Ultrasound of the Prostate: Strategies for Repeat Biopsy. UCLA State of the
`Art Urology. Marina del Ray, CA. March 13, 2005.
`
`Interferon vs. Interleukin-2 Following Nephrectomy for Metastatic Renal Cell
`Carcinoma. Current Treatment Approaches for Renal Cell Carcinoma. Portland, OR,
`March 16, 2005.
`
`Nutritional interventions for prostate cancer prevention and treatment. Jonsson
`Comprehensive Cancer Center Intramural Research Series. May 10, 2005.
`
`Chemoprevention of Bladder Cancer 2005. Second International Congress on Bladder
`and Kidney Cancer. Orlando, FL. July 17, 2005.
`
`Laparoscopic and Ablative Techniques for Small Renal Masses. Hong Kong Urological
`Society. Hong Kong, China, August 30, 2005.
`
`Patient Selection and Predicting Response to IL-2 in Patients with Metastatic Renal Cell
`
`16
`
`32.
`
`
`33.
`
`
`34.
`
`
`35.
`
`
`36.
`
`
`37.
`
`
`38.
`
`
`39.
`
`
`40.
`
`
`42.
`
`
`43.
`
`
`44.
`
`
`45.
`
`
`
`
`41. Molecular profiling, tissue microarray, and proteomic analysis of interleukin-2 complete
`responders in patients with metastatic renal cell carcinoma. Tumor Vaccine and Cellular
`Therapy Working Group. Anaheim, CA. April 15, 2005.
`
`Breckenridge Exhibit 1028
`Pantuck CV
`Page 0016
`
`

`

`Carcinoma. Samsung Medical Center, Seoul, Korea. September 1, 2005.
`
`Patient Selection and Predicting Response to IL-2 in Patients with Metastatic Renal Cell
`Carcinoma. Korean Urological Oncology Society, Seoul, Korea. September 2, 2005.
`
`Nutritional Interventions for prostate cancer prevention and treatment. Ted Mann Family
`Resource Center Insights Into Cancer Series. September 13, 2005.
`
`Pomegranates, Polyphenols, and Prostate Cancer. Grand Rounds, Harbor-UCLA Medical
`Center. January 5, 2006.
`
`Cytreductive nephrectomy: is it still imperative in the era of targeted therapy?
`Innovations and Challenges in Renal Cancer. Second Cambridge Conference. Cambridge,
`MA, April 28, 2006.
`
`Non-surgical approaches to localized RCC: standard of care? Third International
`congress on Kidney and Bladder Cancer. Orlando, FL, August 4, 2006.
`
`A Phase II Open Label Study of CB7630 (Abiraterone Acetate) in Patients with
`Surgically Unresectable, Locally Advanced, and Metastatic Adrenocortical Carcinoma.
`Advancing Treatments for Adrenocortical Carcinoma. Pheonix, AZ, October 20, 2006.
`
`Clinical Trials-The Basics. Society of Urologic Oncology. Bethesda, MD, November 30,
`2006.
`
`Surveillance for RCC: Why and How? When and How Often? Society of Urologic
`Oncology. Bethesda, MD, December 1, 2006.
`
`Lifestyle and dietary interventions for prostate cancer prevention. Yoga Works, Los
`Angeles, CA, March, 2007.
`
`Active Surveillance versus active treatment in the management of the small renal mass.
`American Urological Association, Anaheim, CA, May 23, 2007.
`
`Clinical Characteristics of small renal tumors. 4th International congress on Kidney and
`Bladder Cancer. Orlando, FL, August 4, 2007.
`
`Clinical, Pathological, and Molecular Predictors in RCC. New Technologies and
`Innovative Treatment Strategies for Genitourinary Malignancies. San Diego, CA, Sept.
`29, 2007.
`
`Cytoreductive Nephrectomy: is it still imperative in the era of targeted therapy? Kidney
`
`17
`
`
`49. Minimally Invasive Treatment Options for Renal Cell Carcinoma. 5th Multi-Disciplinary
`Symposium on Genitourinary Cancers. January 27, 2006.
`
`
`46.
`
`
`47.
`
`
`48.
`
`
`50.
`
`
`51.
`
`52.
`
`53.
`
`54.
`
`55.
`
`
`56.
`
`
`57.
`
`
`58.
`
`
`59.
`
`
`
`Breckenridge Exhibit 1028
`Pantuck CV
`Page 0017
`
`

`

`Cancer Association Annual Meeting, Chicago, October 12, 2007.
`
`Pomegranates, NFKB Pathway and Prostate Cancer. JCCC GU Oncology Lecture Series.
`December 4, 2007.
`
`Clinical, Pathologic, and Genetics Predictors of Prognosis for RCC. Harbor Hospital
`Grand Rounds, December 6, 2007.
`
`Pomegranates, NFKB Pathway and Prostate Cancer. Santa Barbara Cancer Center. March
`20, 2008.
`
`Clinical Characteristics of Small Renal Tumors. American Urological Association,
`Orlando, FL, 2008.
`
`Lymph node dissection provides no benefit in the absnce of clinically positive nodes. The
`Seventh International Kidney Cancer Symposium. Chicago, September 26, 2008.
`
`Update of basic and clinical studies of pomegranate juice for prostate cancer. Prostate
`Cancer Annual Retreat, Lake Tahoe, October 16, 2008.
`
`Kidney Cancer Session Panel, Society of Urological Oncology, Bethesda, MD, December
`21, 2008.
`
`Chair Session VII, Management of Multifocal Bilateral Renal Cell Carcinoma, 2009
`American Society of Clinical Oncology Genitourinary Cancers Symposium, Orlando, FL,
`February 28, 2009.
`
`Kidney Cancer Ablation, UCLA State of the Art Urology, Marina del Rey, CA, March
`13, 2009
`
`Course Instructor, Management of the Small Renal Mass, American Urological
`Association Annual Meeting, Chicago, IL, April, 26, 2009.
`
`Abiraterone: current and future trials. Society of Urologic Oncology Annual Spring
`Meeting, Chicago, IL., April 25, 2009.
`
`Is there a role for immunotherapy for metastatic RCC in the era of targeted therapy?
`Asociacion Espanola de Urolgia, Madrid, Spain, May 16, 2009.
`
`Pomegranate polyphenols and kidney cancer. VHL Family Alliance, Anaheim, CA, June
`27, 2009.
`
`60.
`
`61.
`
`
`62.
`
`
`63.
`
`
`64.
`
`
`65.
`
`
`66.
`
`67.
`
`
`68.
`
`69.
`
`
`70.
`
`
`71.
`
`
`72.
`
`
`73. Moderator: Management of locally advanced kidney cancer. Eigth International Kidney
`Cancer Symposium, Chicago, IL, September 26, 2009.
`Cytoreductive nephrectomy. Eigth International Kidney Cancer Symposium, Chicago, IL,
`
`74.
`
`
`
`18
`
`Breckenridge Exhibit 1028
`Pantuck CV
`Page 0018
`
`

`

`September 26, 2009.
`
`Therapeutic Cancer Vaccines for Renal Cell Carcinoma. Cedars Sinai Medical Center
`32nd Annual Bernard Strauss Urology Day. June 10, 2010.
`
`Cancer vaccines: are they ready for prime time? Urology Grand Rounds, Harbor
`Hospital, August 5, 2010.
`
`Integration of systemic therapy with debulking nephrectomy for metastatic RCC—the
`urologist’s viewpoint. Society of Urologic Oncology winter meeting, December 11, 2010.
`
`Active Surveillance Strategies for small renal tumors UCLA State of the Art Urology,
`Marina del Rey, CA, March 13, 2011
`
`Genomic Analysis of RCC. First Annual Kidney Cancer Collaborative Symposium. MD
`Anderson Cancer Center, March 24, 2011.
`
`80. What did he know and when did he know it? Further excavations from the Morton Smith
`archives. The York University Christian Apocrypha Series. Ancient Gospel or Modern
`Forgery? The Secret Gospel of Mark in Debate. Vanier College, Toronto, Canada, April
`29, 2011.
`
`Update on Targeted Therapy for Advanced Disease. Society of Urologic Oncology,
`American Urolgical Association, Washington, DC, May, 2011.
`
`Non-clear cell and hybrid carcinoma: a separate biology? Association